Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004.

Schneider MF, Gange SJ, Williams CM, Anastos K, Greenblatt RM, Kingsley L, Detels R, Muñoz A.

AIDS. 2005 Nov 18;19(17):2009-18.

PMID:
16260908
2.
3.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
4.

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC.

AIDS. 2003 Dec 5;17(18):2615-22.

PMID:
14685055
5.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
6.

Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.

Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2007 Mar;8(2):75-9.

7.

Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.

Anastos K, Barrón Y, Miotti P, Weiser B, Young M, Hessol N, Greenblatt RM, Cohen M, Augenbraun M, Levine A, Muñoz A; Women's Interagency HIV Study Collaborative Study Group.

Arch Intern Med. 2002 Sep 23;162(17):1973-80.

PMID:
12230420
9.

The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy.

Dorrucci M, Valdarchi C, Suligoi B, Zaccarelli M, Sinicco A, Giuliani M, Vlahov D, Pezzotti P, Rezza G.

AIDS. 2004 Nov 19;18(17):2313-8.

PMID:
15577544
10.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
11.

AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?

Sabine C; Antiretroviral Therapy (ART) Cohort Collaboration.

AIDS. 2005 Nov 18;19(17):1995-2000.

PMID:
16260906
12.

Effectiveness of highly-active antiretroviral therapy by race/ethnicity.

Silverberg MJ, Wegner SA, Milazzo MJ, McKaig RG, Williams CF, Agan BK, Armstrong AW, Gange SJ, Hawkes C, O'Connell RJ, Ahuja SK, Dolan MJ; Tri-Service AIDS Clinical Consortium Natural History Study Group.

AIDS. 2006 Jul 13;20(11):1531-8.

PMID:
16847408
13.

Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.

Gerna G, Piccinini G, Genini E, Percivalle E, Zavattoni M, Lilleri D, Testa L, Comolli G, Maserati R, Baldanti F, Maccario R, Monforte AD, Revello MG.

J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):320-31.

PMID:
11707667
14.

Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.

J Infect Dis. 2007 Oct 1;196(7):1044-52. Epub 2007 Aug 29.

PMID:
17763327
15.

Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.

Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA.

AIDS. 2000 Aug 18;14(12):1829-37.

PMID:
10985321
16.

[Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].

Pozio E.

Parassitologia. 2004 Jun;46(1-2):89-93. Review. Italian.

PMID:
15305694
17.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
18.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.

PMID:
16878047
19.

Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome.

Sungkanuparph S, Chakriyanuyok T, Butthum B.

J Infect. 2008 Jan;56(1):40-3. Epub 2007 Nov 26.

PMID:
18037166
20.

Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts.

Tarwater PM, Mellors J, Gore ME, Margolick JB, Phair J, Detels R, Muñoz A.

Am J Epidemiol. 2001 Oct 1;154(7):675-81.

PMID:
11581102

Supplemental Content

Support Center